MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...
Miami Herald3d
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and ...
Yahoo Finance3d
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
This advancement expands the Company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief.
Mira Pharmaceuticals expands Ketamir-2 development with topical treatment
MIRA Pharmaceuticals (MIRA) announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain.
Finanznachrichten3d
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
Current treatment options for localized neuropathic and inflammatory pain-including NSAIDs, lidocaine patches, capsaicin creams, gabapentin, pregabalin, and opioids-offer limited relief and come ...